001     283110
005     20260102125119.0
024 7 _ |a 10.1002/alz70855_106193
|2 doi
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
037 _ _ |a DZNE-2026-00006
082 _ _ |a 610
100 1 _ |a Song, Xiaoxuan
|0 P:(DE-2719)9002968
|b 0
|e First author
|u dzne
111 2 _ |a Alzheimer’s Association International Conference
|g AAIC 25
|c Toronto
|d 2025-07-27 - 2025-07-31
|w Canada
245 _ _ |a Alpha‐Synuclein co‐pathology drives tau accumulation in Alzheimer's disease patients and iPSCs‐derived models
260 _ _ |c 2025
336 7 _ |a Abstract
|b abstract
|m abstract
|0 PUB:(DE-HGF)1
|s 1767354615_32512
|2 PUB:(DE-HGF)
336 7 _ |a Conference Paper
|0 33
|2 EndNote
336 7 _ |a INPROCEEDINGS
|2 BibTeX
336 7 _ |a conferenceObject
|2 DRIVER
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|m journal
336 7 _ |a Output Types/Conference Abstract
|2 DataCite
336 7 _ |a OTHER
|2 ORCID
520 _ _ |a Background:The molecular basis for accelerated cognitive decline seen in Alzheimer's Disease (AD) cases presenting with cortical alpha-Synuclein co-pathology is not well understood. Mouse experiments have shown adverse interactions between tau (encoded by MAPT) and alpha-Synuclein (encoded by SNCA), but how this finding translates to humans from a genome-centered point of view remains unknown.Method:Whole genome sequencing was performed on 137 neuropathologically defined AD cases, 36 of which presented with neocortical alpha-Synuclein co-pathology (Braak stage 6). Polygenic risk scores were calculated. Single-nucleus RNA sequencing and Western Blot data were collected from post-mortem tissue. Transcriptomic and proteomic results were validated in the MSBB cohort (n >300). Cellular, molecular and epigenetic consequences were assessed in isogenic iPSCs-derived neurons carrying a triplication of SNCA (AST) or a normal SNCA copy number (CAS).Result:AD brains with alpha-Synuclein co-pathology had significantly higher polygenic risk scores for Parkinson's Disease, which could be partially explained by variants associated with higher expression of SNCA. Single-nucleus RNA sequencing and immunoblot analysis revealed a higher expression of MAPT and phosphorylated tau in alpha-Synuclein co-pathology cases. Protein and mRNA expression of MAPT and SNCA were positively correlated in the MSBB cohort. The employed iPSCs differentiation protocol accelerated neuronal maturation due to transient inhibition of EZH2. Day50 AST neurons exhibited significantly increased pathological tau and alpha-Synuclein at both the RNA and protein levels compared to CAS neurons. AST neurons also showed highly activated GSK3β and decreased PSD95 (post-synaptic protein) in the immunofluorescence and immunoblot analyses. ATAC profiles identified dysregulated accessibility in the cAMP signaling pathway, as well as pathways related to axon guidance, postsynaptic density, and calcium signaling, among others.Conclusion:We demonstrate that alpha-Synuclein co-pathology in AD is characterized by higher phosphorylated tau levels in patients and iPSC-derived neurons. Our results provide insights into the complex molecular processes through which alpha-Synuclein and tau synergistically drive dementia-related pathology.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
700 1 _ |a de Vecchi, Teodoro
|0 P:(DE-2719)9002143
|b 1
|u dzne
700 1 _ |a Widmann, Jeannine
|0 P:(DE-2719)9000813
|b 2
700 1 _ |a Fierli, Federico
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Ruf, Viktoria
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Tang, Qilin
|0 P:(DE-2719)9001127
|b 5
700 1 _ |a Arzberger, Thomas
|0 P:(DE-2719)2811333
|b 6
|u dzne
700 1 _ |a Roeber, Sigrun
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Köglsperger, Thomas
|0 P:(DE-2719)2810825
|b 8
|u dzne
700 1 _ |a Windl, Otto
|0 P:(DE-2719)2812263
|b 9
700 1 _ |a Haass, Christian
|0 P:(DE-2719)2202037
|b 10
|u dzne
700 1 _ |a Winkelmann, Juliane
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Herms, Jochen
|0 P:(DE-2719)2810441
|b 12
|u dzne
700 1 _ |a Strübing, Felix
|0 P:(DE-2719)2813904
|b 13
|e Last author
|u dzne
773 _ _ |a 10.1002/alz70855_106193
|g Vol. 21, no. S1, p. e106193
|0 PERI:(DE-600)2201940-6
|n S1
|p e106193
|t Alzheimer's and dementia
|v 21
|y 2025
|x 1552-5260
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/283110/files/DZNE-2026-00006.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/283110/files/DZNE-2026-00006.pdf?subformat=pdfa
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9002968
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9002143
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9000813
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9001127
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 6
|6 P:(DE-2719)2811333
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2810825
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2202037
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 12
|6 P:(DE-2719)2810441
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2813904
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
920 1 _ |0 I:(DE-2719)1110001
|k AG Herms
|l Translational Brain Research
|x 0
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 1
980 _ _ |a abstract
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a journal
980 _ _ |a I:(DE-2719)1110001
980 _ _ |a I:(DE-2719)1111015
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21